Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK19 | Q9BWU1 | 2/20 | 0.54 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.54 |
| ▸ | CDK2 | P24941 | 3/20 | 0.44 |
| ▸ | CDK4 | P11802 | 2/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.43 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.43 |
| ▸ | IGF1R | P08069 | 6/20 | 0.42 |
| ▸ | INSR | P06213 | 2/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
| ▸ | JAK1 | P23458 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 2/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3760388 | 0.89 | CDK19 (0.58) | CDK19ALKCDK2CDK4CCNE1 | |
| SCHEMBL3756888 | 0.88 | CDK19 (0.46) | CDK19ALKCDK2CDK4CCNE1 | |
| SCHEMBL3716771 | 0.86 | CDK19 (0.66) | CDK19ALKCDK2CDK4CCNE1 | |
| SCHEMBL3725893 | 0.82 | CDK19 (0.59) | CDK19ALKCDK2CDK4CCNE1 | |
| SCHEMBL3760617 | 0.81 | CDK19 (0.43) | CDK19ALKCDK2CDK4CCNE1 | |
| SCHEMBL3755303 | 0.80 | CDK2 (0.52) | CDK2CDK4CCNE1CDK1IKBKE | |
| SCHEMBL3761154 | 0.80 | IGF1R (0.44) | CDK19ALKCDK2CDK4CCNE1 | |
| SCHEMBL3761708 | 0.79 | CDK19 (0.53) | CDK19ALKCDK2CDK4CCNE1 | |
| SCHEMBL3725891 | 0.79 | CDK19 (0.56) | CDK19ALKCDK2CDK4CCNE1 | |
| SCHEMBL3719752 | 0.79 | CDK19 (0.57) | CDK19ALKCDK2CDK4CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435436-B1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBVIE INC (US) | 2014-07-30 | — | — | EP | claimed |
| US-8354422-B2 | Pyrimidine inhibitors of kinase activity | ABBOTT LABORATORIES INC. (US) | 2013-01-15 | — | — | US | claimed |
| WO-2010138576-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | claimed |
| US-20100305126-A1 | Pyrimidine Inhibitors of Kinase Activity | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | claimed |
| EP-2435436-B1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBVIE INC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-8354422-B2 | Pyrimidine inhibitors of kinase activity | ABBOTT LABORATORIES INC. (US) | 2013-01-15 | — | — | US | disclosed |
| WO-2010138576-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305126-A1 | Pyrimidine Inhibitors of Kinase Activity | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305126-A1 | Pyrimidine Inhibitors of Kinase Activity | IGF1R, CDK2, TK1 | CDK19 53/4885ALK 534/4885CDK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.